Johnson & Johnson MedTech’s Biosense Webster division presented new clinical data backing up its pulsed field ablation ...

Johnson & Johnson MedTech’s Biosense Webster shared results from a clinical trial of its Varipulse pulsed field ablation (PFA ...

Clinical outcomes are excellent with use of radiofrequency (RF) catheter ablation (CA) for paroxysmal atrial fibrillation ...

New CARTO™ 3 System Version 8 software introduces machine learning capabilities Increases efficiency, reproducibility, and ...

Once again, the top players in cardiac care gathered en masse as Heart Rhythm Society (HRS) 2024 took place in Boston last ...

Irvine: Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, has ...

Using real world clinical data, Brigham researchers found that 82 percent of patients had one year free from atrial fibrillation after an ablation procedure with procedural complications under 2 perce ...

Johnson & Johnson MedTech’s Biosense Webster division is rolling out a new version of its heart-mapping system that the company says marks its first to employ artificial intelligence capabilities.

Cardiac arrhythmia diagnosis and treatment specialist Biosense has launched CARTO 3 System Version 8, a 3D heart mapping system used in cardiac ablation procedures. This latest version introduces new ...

IRVINE, Calif., May 8, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO ™ 3 ...